Join the Semler Scientific (SMLR) Securities Class Action Lawsuit

Shamis & Gentile P.A., one of the nation's premier class action law firms specializing in securities fraud cases, is investigating potential claims against Semler Scientific Inc. (SMLR)

If you purchased or held Semler Scientific Inc. securities between March 10, 2021 and April 15, 2025, you may be eligible to join this class action lawsuit and seek compensation for your losses.

About Semler Scientific Inc.

Semler Scientific is a medical technology company based in Campbell, California. Founded in 2010, the company focuses on developing and marketing diagnostic tools for healthcare providers, with a particular emphasis on chronic disease management.

Its flagship product, QuantaFlo®, is a patented and FDA-cleared device designed to measure arterial blood flow in the extremities and assist in diagnosing cardiovascular conditions.

The Allegations

The class action lawsuit alleges that Semler Scientific and certain executives failed to disclose a material investigation by the U.S. Department of Justice (DOJ) into potential False Claims Act violations related to its QuantaFlo product. Instead, the company discussed such risks only in hypothetical terms in its SEC filings, omitting the fact that an actual DOJ investigation was underway.

During the class period (March 10, 2021 to April 15, 2025) Semler Scientific’s public statements are alleged to have been materially false and misleading. The complaint points out that the DOJ issued multiple civil investigative demands between 2021 and 2023, yet these were not disclosed to investors at the time.

The truth began to emerge in early 2025, when Semler Scientific revealed the existence of the DOJ investigation and ongoing settlement discussions. Shortly after these disclosures, the company announced an agreement in principle to pay $29.75 million to settle the DOJ claims.

Following these revelations, Semler Scientific’s stock price fell sharply. On March 3, 2025, after news of the investigation surfaced, the stock dropped 9.38%. Then, on April 16, 2025, after the settlement amount was disclosed, the stock fell another 9.88%. These declines resulted in significant losses for investors who purchased shares during the class period.

Important Dates

• Class period: March 10, 2021 to April 15, 2025
• Lead plaintiff deadline: October 28, 2025
• Complaint filed: August 29, 2025

Your Rights and Next Steps

If you purchased or otherwise acquired Semler Scientific securities during the class period, you have important legal rights. As an investor, you may be eligible to join this class action lawsuit and seek compensation for your financial losses resulting from the alleged securities fraud.

To participate, you do not need to take any action to remain a member of the class. However, if you wish to serve as the lead plaintiff (the representative who acts on behalf of all class members) you must file a motion with the court by October 28, 2025. The lead plaintiff is typically the investor with the largest financial interest in the case and plays a key role in directing the litigation.

Lawyers are ready to help guide you through the process, explain your options, and answer any questions you may have about your eligibility. Even if you are unsure about your losses or your eligibility, submitting your information is the first step to protecting your rights.

You May Be Entitled to Compensation

If you suffered losses in Semler Scientific securities during the class period, you may be entitled to compensation. Lawyers are ready to help you understand your legal options and pursue a recovery on your behalf.

To get started, complete the below form to join the lawsuit and ensure your interests are represented.